Background:. Idiopathic pulmonary fibrosis (IPF) is a complicated disease in which histopathological abnormalities in the form of, proliferation of mesenchymal cell, fibrosis, overproduction and disorganization of collagen deposition, extra cellular matrix changes with distortion of pulmonary structure and the appearance of subpleural cysts , with accumulation of both myofibroblast and fibroblast. Pirfenidone has been available in Japan since 2008.In 2011, the approval by the European Medicine Agency (EMA) was indicated by the efficacy of pirfenidone in decreasing lung function deterioration in IPF patients.
INTRODUCTION
diopathic pulmonary fibrosis (IPF) is nonpredictable, irreversible, debilitating and finally it is a fatal chronic fibrotic lung disease associated with dyspnea and a progressive reduction in lung function. From all forms of idiopathic interstitial pneumonias, idiopathic pulmonary fibrosis is considered the most frequent and fatal form , although the clinical course varies, prognosis is poor with a median survival from the onset of symptoms of only 2.8-4.2 years (1) . Early, IPF was considered to be an inflammation-driven disorder so initial treatment aimed to defeat and suppress the inflammatory process (e.g. corticosteroids and immunomodulatory agents) ,However, there is a new clue that inflammation is not a major histopathological finding in UIP and that fibroblast foci develop early in UIP (2) Pirfenidone was the first approved antifibrotic agent for the treatment of IPF. It was approved in 2008 and gave the hope for IPF patients and physicians for a new era in the treatment of IPF (3), The (6) . Pirfenidone therapy is started with a 14-day titration regimen of 801 mg/day (one capsule, three times per day) on days 1-7 of 1,602 mg/day (two capsules, three times per day) on days 8-14. The daily dose from day 15 onwards is pirfenidone2,403 mg/day (three capsules, three times per day) STATISTICAL ANALYSES All statistical analyses were carried out using the SPSS (statistical package for the social science software) statistical package version 20.0 (SPSS Inc., Chicago, IL, USA) for Windows. Quantitative data were expressed as mean and standard deviation (X + SD) and analyzed by applying student t-test for comparison of two groups of normally distributed variables. The results of the "t"-value is then checked on student's "t"-table to find out the significance level (p-value) according to the degree of freedom. 100.0% 100.0% This table shows Socio-demographic data of both patients' groups Most of patients were females (26 patients) with percentage of 65%, 13 in group (A) and 13 in group (B), none of the patients was current smoker , 15 patients were nonsmokers with percentage of 37.5%, 10 in group (A) and 5 in group (B), 10 patients were Ex-smokers with percentage of 25%, 4 in group (A) and 6 in group (B), 10 patients had DM with percentage of 25%, 3 in group (A) and 7 in group (B), while 11 patients had hypertension with percentage of 27.5%, 3 in group (A) and 7 in group (B), no statistical significant differences regarding sex, special habits and (P>0.05) but there was significant statistical difference between patients' groups according to comorbidities (P<0.05). This table shows that there is no change in distance of the six minutes walk test in pirfenidone group after treatment but there is loss in distance of the six minutes walk test in other group after treatment with no statistical significant differences between two groups (P>0.05) .
RESULTS
For Oxygen saturation the table shows loss in both groups after treatment but the loss in pirfenidone group was less than other group with no statistical significant differences between two groups (P>0.05) This table show grades of Dyspnea according to mMRC before and after treatment among studied groups with no statistical significant differences between two groups neither before nor after treatment (P>0.05).
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January This table shows the mean weight of two groups before and after which found 88.2 ± 15.83 KG for group (A) and 84.25± 13.96 for group (B) before treatment and 85.95±15.62 KG for group (A) and 88.1± 14.57 for group (B) after treatment there is a weight gain in patients of group (B) and weight loss in patients of group (A) with no statistical significant differences between two groups after treatment (P>0.05). DISCUSSION Idiopathic pulmonary fibrosis (IPF) is a specific form of fibrosed interstitial pneumonia which is progressive, chronic and its cause isn't known. It is limited to the lungs, occurs mainly in older adults and is associated with histological and/or radiological characteristics of usual interstitial pneumonia (UIP) (7)
Although the disease has been considered rare, it occurs with same rate of stomach, brain, and testicular cancers (8) . After the explanation of the nature of the disease that appears to be related to inflammation and fibrosis, this gives us the idea to begin the "anti-fibrotic" era (9) .
These are in agreement with Suraj et al., (2015) (10). In this Indian study of 23 IPF patients who were followed up for one year, female patients were 54%. Patients had DM (12.5%) and hypertension (12.5%). Salih et al., (2016) (11) reported that none of their IPF patients were current smokers. who found significant improvement in distance walked during 6MWD test in pifenidone group. The explanation of previous results was that the sample size of current study was small compared to the other, the duration of current study was only 3 months and patient were proved only according to definite pattern of UIP on HRCT. The main side effect of steroids is increasing of weight Weight loss is a side effect of pirfenidone. This was reported in previous studies 
